# Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

> **NCT00703326** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1144 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** ramucirumab (IMC-1121B)
- **DRUG:** docetaxel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00703326
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-06
- **Primary completion:** 2013-03-31
- **Final completion:** 2020-11-19
- **Target enrollment:** 1144 (ACTUAL)
- **Last updated:** 2021-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703326, "Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00703326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*